COMPAZINE
LOE ApproachingNDAORALTABLETPriority Review
Approved
Oct 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMPAZINE (prochlorperazine) is an oral small-molecule antipsychotic and antiemetic approved in 1956 by GSK. The exact mechanism of action is not specified in available data, but it is a phenothiazine-class agent used across multiple indications. Patient eligibility and specific therapeutic uses require review of current labeling.
LOE Approaching
As LOE approaches, brand teams face declining revenue and shrinking headcount; focus shifts to cost management and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on COMPAZINE offers limited career advancement due to its LOE-approaching status and minimal linked job openings (0). Positions focus on stewardship, compliance, and managed decline rather than innovation or growth—suitable for stable, defensive roles but not optimal for career acceleration.
Brand Manager (Lifecycle Management)Field Sales Representative
Worked on COMPAZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.